Lenalidomide: A synthetic compound with an evolving role in cancer management

Hematology

Volumn 15, Issue 5, 2010, Pages 318-331

  Saloura, Vassiliki ^a   Grivas, Petros D ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

Author keywords

Lenalidomide; leukemia; lymphoma; multiple myeloma; myelodysplasia

Indexed keywords

BORTEZOMIB; CLARITHROMYCIN; DEXAMETHASONE; FLUDARABINE; LENALIDOMIDE; MELPHALAN; PLACEBO; PREDNISONE; RITUXIMAB; THALIDOMIDE;

5Q- SYNDROME; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMYLOIDOSIS; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANXIETY; ARTHRALGIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; CYTOPENIA; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; GLIOMA; HEART ATRIUM FIBRILLATION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOTHYROIDISM; IMMUNOMODULATION; INFECTION; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG EMBOLISM; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCLE WEAKNESS; MYELOFIBROSIS; MYELOID METAPLASIA; MYOPATHY; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SEDATION; SIDE EFFECT; SKIN DISEASE; SOLID TUMOR; STROKE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TUMOR FLARE; VASCULITIS; WALDENSTROEM MACROGLOBULINEMIA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; HEMATOLOGIC DISEASES; HUMANS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROMES; NEOPLASMS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 77957317687     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453310X12647083620921     Document Type: Review

References (80)

1. Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357(21):2123- 2132.
2. Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357(21):2133-2142.
3. Mitsiades CS, Mitsiades N. CC-5013 (Celgene). Curr Opin Investig Drugs 2004;5(6):635-647.
4. Teo SK, Oliver J, Harden D, Stirling D, Thoms S, Scheffler M. A phase I, single blind, placebo-controlled, ascending single oral dose, safety, tolerabilility and pharmakokinetic study of CDC-501, a novel immunomodullatory-oncologic agent, in health male subjects with a comparison of fed and fasted. Clin Pharm Ther 2002;71(2):93.
5. Kotla V, Goel S, Nischal S et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009;2:36.
6. Muller GW, Chen R, Huang SY et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999;9(11):1625-1630.
7. Symeonidis A, Kourakli A, Katevas P et al. Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis. Eur J Haematol 1991;47(4):277-281.
8. Chanan-Khan A, Miller KC, Musial L et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24(34):5343-5349.
9. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 1995;162(2):248-255.
10. Corral LG, Haslett PA, Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163(1):380-386.
11. LeBlanc R, Hideshima T, Catley LP et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004;103(5):1787-190.
12. Dredge K, Marriott JB, Todryk SM et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 2002;168(10):4914-4919.
13. Stirling D. Thalidomide: a novel template for anticancer drugs. Semin Oncol 2001;28(6):602-606.
14. Davies FE, Raje N, Hideshima T et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98(1):210-216.
15. Hayashi T, Hideshima T, Akiyama M et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005;128(2):192-203.
16. Bartlett JB. Lenalidomide enhances tumor killing in vitro during ADCC mediated by Trastuzumab, Cetuximab, and Rituximab. J Clin Oncol 2007;25(18S):3023.
17. Gupta D, Treon SP, Shima Y et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001;15(12):1950-1961.
18. Giagounidis AA, Germing U, Haase S et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del (5q) including band q31. Leukemia 2004;18(1):113-119.
19. Buesche G. Anti-angiogenic in vivo effect of lenalidomide in MDS with del (5q) chromosome abnormality. Oral Abstract Session ASCO 2007 2007.
20. + progenitor cells. Cancer Res 2007;67(2):746-755.
21. Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96(9):2943-2950.
22. Chanan-Khan A. Pro-Apoptotic effect of Lenalidomide in patients with Chronic Lymphocytic Leukemia is possibly mediated through interruption of Phosphatidylinositol pathway. Blood (ASH annual meeting abstracts) 2006, 108.
23. Pellagatti A, Jadersten M, Forsblom AM et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients. Proc Natl Acad Sci USA 2007;104(27):11406-11411.
24. Ebert BL, Galili N, Tamayo P et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008;5(2):e35.
25. List A, Kurtin S, Roe DJ et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352(6):549-557.
26. List A, Dewald G, Bennett J et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355(14):1456-1465.
27. List A, Dewald G, Bennett J. Clinical benefit from 2 phase II trials evaluating lenalidomide (Revlimid) in lower-risk myelodysplastic syndrome patients with or without del 5q cytoenetic abnormalities (abstract). European Hematology Association 11th Congress Proceedings; 2006 June 15-18; Amsterdam, The Netherlands. EHA, Abstract 1032.
28. List A. Treatment and prognosis of the myelodysplastic syndromes. Proceeding of 9th International Symposium on MDS; May 2007; Florence, Italy.
29. Ades L, Boehrer S, Prebet T et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 2009;113(17):3947-3952.
30. Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106(8):1794-1803.
31. Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20(10):2429-2440.
32. Jonásova A, Neuwirtová R, Cermák J et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998;100(2):304-309.
33. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997;99(3):699-705.
34. Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106(13):4050-4053.
35. Rajkumar SV, Jacobus S, Callender N et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group (abstract). J Clin Oncol 2007;25:968s.
36. Niesvizky R, Jayabalan DS, Christos PJ et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008;111(3):1101-1109.
37. Wang M, Delasalle K, Giralt S, Alexanian R. Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). Blood 2007;110:(Abstract no. 3611).
38. Richardson P, Hagannath S, Raje N et al. Lenalidomide, bortezomib and dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MML): preliminary results of a phase 1/2 study. Blood 2007; 110 (Abstract no. 187).
39. Palumbo A, Falco P, Corradini P et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007;25(28):4459-4465.
40. Richardson P, Jagannath S, Hussein M et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009;114(4):772-778.
41. Richardson PG, Blood E, Mitsiades CS et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108(10):3458-3464.
42. Miguel JFS, Dimopoulos M, Weber D et al. Dexamethasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/ dezamethasone (MM009/010 sub-analysis). Blood 2007;110:(Abstract no. 2712).
43. Knop S, Gerecke C, Topp MS et al. Lenalidomide, adriamycin and dexamethasone chemotherapy (RAD) is safe and effective in treatment of relapsed multiple myeloma-First results of a German multicenter Phase I/II Trial. Blood 2006;108:(Abstract no. 408).
44. Morgan GJ, Schey SA, Wu P et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007;137(3):268-269.
45. Baz R, Walker E, Karam MA et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006;17(12):1766-1771.
46. Chanan-Khan A, Porter CW. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol 2006;7(6):480-488.
47. Richardson P, Jagannath S, Raje N et al. Lenalidomid, bortezomib and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): preliminary results of a phase II study. Blood 2007;110:(Abstract no. 2714).
48. Richardson PG, Jagannath S, Avigan DE et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial. Blood 2006;108:(Abstract no. 405).
49. Ferrajoli A, Lee BN, Schlette EJ et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111(11):5291-5297.
50. Ferrajoli A, O'Brien S, Wierda W et al. Lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia (CLL). Blood 2008, 112, 23.
51. Chen C, Paul H, Xu W et al. A phase II study of lenalidomide in previously untreated, symptomactic chronic lymphocytic leukemia (CLL). Blood 2008;112:23.
52. Andritsos LA, Johnson AJ, Lozanski G et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26(15):2519-2525.
53. Arana-Yi C, Quintas-Cardama A, Giles F et al. Advances in the therapy of chronic idiopathic myelofibrosis. Oncologist 2006;11(8):929-943.
54. Tefferi A, Cortes J, Verstovsek S et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108(4):1158-1164.
55. Treon SP, Soumerai JD, Branagan AR et al. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009;15(1):355-360.
56. Treon SP, Soumerai JD, Branagan AR et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008;112(12):4452-4457.
57. Wiernik PH, Lossos IS, Tuscano JM et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26(30):4952-4957.
58. Goy A, Younes A, McLaughlin P et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23(4):667-675.
59. Fosså A, Santoro A, Hiddemann W et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non- Hodgkin's lymphoma. J Clin Oncol 1999;17(12):3786-3792.
60. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92(6):1927-1932.
61. Habermann TM, Lossos IS, Justice G et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145(3):344-349.
62. Fisher RI, Bernstein SH, Kahl BS et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24(30):4867-4874.
63. Witzig TE, Geyer SM, Ghobrial I et al. Phase II trial of singleagent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23(23):5347-5356.
64. Wang M, Fayad L, Hagemeister F. A phase I/II study of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma with early evidence of efficacy. J Clinic Oncol 2007;25:448s (suppl; abstr 8030).
65. Dispenzieri A, Lacy MQ, Zeldenrust SR et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109(2):465-470.
66. Sanchorawala V, Wright DG, Rosenzweig M et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007;109(2):492-496.
67. Miller AA, Case D, Harmon M et al. Phase I study of lenalidomide in solid tumors. J Thorac Oncol 2007;2(5):445-449.
68. Dahut WL, Aragon-Ching JB, Woo S et al. Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol 2009;49(6):650-660.
69. Fine HA, Figg WD, Jaeckle K et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent highgrade gliomas. J Clin Oncol 2000;18(4):708-715.
70. Fine HA, Kim L, Albert PS et al. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin Cancer Res 2007;13(23):7101-7106.
71. Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17(9):2859-2867.
72. Dexeus FH, Logothetis CJ, Sella A et al. Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. J Urol 1991;146(3):709-713.
73. Mertens WC, Eisenhauer EA, Moore M et al. Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1993;4(4):331-332.
74. Gordon MS, Manola J, Fairclough D et al. Low dose interferon a2b (IFN) +thalidomide in patients with previously untreated renal cell cancer (RCC). Improvement in progression-free survival but not quality of life or overall survival. A phase IIi study of the Eastern Cooperative Oncology Group (E2898) (abstract). Proc Am Soc Clin Oncol 2004;22:386s.
75. Choueiri TK, Dreicer R, Rini BI et al. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 2006;107(11):2609-2616.
76. Amato RJ, Hernandez-McClain J, Saxena S, Khan M. Lenalidomide therapy for metastatic renal cell carcinoma. Am J Clin Oncol 2008;31(3):244-249.
77. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213.
78. Zhang MM, Chan JK, Husain A, Guo HY, Teng NN. Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma. Gynecol Oncol 2007;105(1):194-198.
79. Dimopoulos MA, Kastritis E, Rajkumar SV. Treatment of plasma cell dyscrasias with lenalidomide. Leukemia 2008;22(7):1343-1353.
80. Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006;108(1):403.